MedTrace Logo

A Study of Ivonescimab in People With Leiomyosarcoma

NCT07516925 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-08

No results posted yet for this study

Summary

The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.

Conditions

  • Leiomyosarcoma

Interventions

DRUG

Ivonescimab

Ivonescimab is administered IV Q3W on Day 1 of each cycle

Sponsors & Collaborators

Principal Investigators

  • Sandra D'Angelo, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2029-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07516925 on ClinicalTrials.gov